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Objective: Soy and cocoa have been suggested to be beneficial for diabetes. The aim
of this study was to identify the effects of soy protein, isoflavones, and cocoa on glycemic
control parameters.
Research design and methods: The study was a parallel, double-blind,
placebo-controlled study where patients with diet or metformin controlled type 2 diabetes
were randomized to, casein soy protein with or without isoflavones (SPI, SP), and
with or without cocoa (SPIC, SPC) arms for an 8 week period. Glycemic control and
cardiovascular risk factors were assessed prior to and after the completion of the dietary
intervention. Sixty participants completed the study.
Results: Soy protein improved HbA1c compared to casein (p < 0.05). The addition of
isoflavones improved indices of insulin resistance and LDL [delta QUICKIE (SPI:−0.12 ±
0.04 vs. SP: 0.03± 0.06, p= 0.03); delta LDL (−0.27± 0.41 vs. 0.22± 0.43, p= 0.02);
percentage change in HOMA (31.02± 54.75 vs.−14.42± 27.07, p= 0.02); percentage
change in QUICKIE (−3.89 ± 7.07 vs. 6.11 ± 10.54, p = 0.01)]. However, the addition
of cocoa provided no benefit with or without isoflavones.
Summary: Soy protein had intrinsic activity on glycemic control compared to casein.
Isoflavones improved both insulin resistance and LDL, but cocoa did not have added
benefit on these indices.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT01754662.
Keywords: type 2 diabetes, soy, cocoa, glycemia control, isoflavones
INTRODUCTION
The number of patients with diabetes is projected to rise to 592 million in the next 25 years (1). The
prevalence of cardiovascular disease is three times higher in patients with type 2 diabetes (2) with a
four-to six-fold higher mortality (3).
Lifestyle and diet modification remains the first step in improving glycemic control and soy has
been shown to improve insulin resistance in both primate studies and post-menopausal women
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(4–7). Other animal studies have suggested that diets containing
soy result in an improvement in insulin sensitivity, glycemic
control and a decrease in fasting insulin levels (8–11). In vitro
data suggests that the glycemic action of soy phytoestrogens may
be due to their α-glucosidase inhibitory effects, inhibition of the
glucose uptake at the intestinal brush border, and a tyrosine
kinase inhibitory action (12–14).
Consumption of soy has been suggested to have an inverse
relationship with mortality from CVD perhaps through a
favorable effect on lipid levels and glycemic control. However,
a meta-analysis of various soy preparations with a wide range
of soy protein and isoflavone intake, did not support LDL
or HDL cholesterol changes in response to soy-associated
isoflavones (15), and isoflavones given alone also appeared to
be ineffective (16). However, a major confounding issue is
that all of the studies to date have been undertaken with soy
protein that will also contain isoflavones and there are no
studies with soy protein alone that is confirmed to be free
from isoflavones.
Cocoa, with high polyphenol content, is potentially beneficial
for patients with type 2 diabetes with improvement of
cholesterol levels, blood pressure, insulin resistance, and
overall cardiovascular risk reduction (17–20). A meta-analysis
concluded that chocolate or cocoa improve flow-mediated
vasodilatation, fasting insulin, and insulin resistance (21). A
recent study reported that an isoflavones and flavanols product
over a 1-year period improved multiple cardiovascular risk
factors in post-menopausal women (22), and others reported
an improvement in endothelial dysfunction in diabetes patients
given high polyphenol chocolate (23), though another study
found only a change in HDL.
Given the limited data on the combination of soy
protein isoflavones and cocoa on glycemic control and
cardiovascular risk parameters in type 2 diabetes, this study
was therefore undertaken.
RESEARCH DESIGN AND METHODS
Patients
Eighty-four patients with diet- or metformin controlled type 2
diabetes aged 45–80 were consecutively recruited to the study
through routine diabetes clinics and local media advertisement.
Seventy patients were randomized and sixty patients completed
the study (Supplementary Information).
The diagnosis of diabetes was made according to the WHO
guidelines (24). Patients were either diet controlled (n = 24) or
on stable metformin therapy (n= 36) for at least 3 months before
study commencement, and medication was not altered over the
study period.
Inclusion criteria were type 2 diabetes on diet alone or
stable metformin therapy, men, and post-menopausal women.
Exclusion criteria: premenopausal women, women on hormonal
replacement therapy within the preceding 6 months, smokers,
vegans, vegetarians, patients with regular soy consumption, and
patients with allergy to any nutritional component of the study
bars were excluded during the screening process. Antibiotic
treatment within the previous 3 months, or during the study,
was an exclusion criterion as antibiotics have been shown to
alter isoflavone metabolism and absorption through interference
with gut flora (25). Concomitant participation in any other
interventional medical trial was not allowed.
All subjects gave written informed consent in accordance
with the International Conference of Harmonization Good
Clinical Practice (ICH GCP) and the Declaration of Helsinki
(ClinicalTrials.gov Identifier: NCT01754662). The protocol was
approved by the Humber Bridge Regional Ethics Committee
(11/YH/0219). The conduct of the trial was in accordance with
all relevant legislation.
Study Protocol
This was a randomized, parallel, double-blind, placebo-
controlled clinical trial. Following informed consent and
eligibility screening, patients met with a dietitian who explained
the need to avoid dietary products with a high isoflavone-content
and to maintain their current diet and level of physical activity.
Blood samples were taken after an overnight fast during Visit
2 (week 2) and Visit 4 (week 10). Weight and blood pressure
were also recorded. Compliance was checked by collecting and
counting empty wrappers, and uneaten bars.
The randomization was performed by Essential Nutrition
Ltd, UK. A computer generated randomization list was used
to provide balanced blocks of patient numbers for each of
the groups. A 1:1:1:1:1 treatment allocation was used without
revealing the block size. Patients were randomized consecutively
during Visit 2 by the study staff, when the next available
randomization number was assigned.
Intervention
Patients were randomized to casein protein as placebo (P)
(n= 11), soy protein alone that was isoflavone free (SP) (n= 15),
soy protein + isoflavones (SPI) (n = 16), soy protein + cocoa
(SPC) (n = 13), or soy protein+isoflavones + cocoa (SPIC)
(n= 15) groups.
Two bars containing a base of 7.5 g (15 g daily) of 70%
isolated soy protein powder (Solcon F; CHS Ashdod, Israel)
with or without added isoflavones (Solgen 16mg per bar, 32mg
in total daily; CHS Ashdod, Israel) with or without 400mg of
cocoa polyphenols in 1.6 g of cocoa powder (CocoanOX 12%,
Natraceutical S. A., Barcelona, Spain) were given twice daily
(mid-morning and mid-afternoon) for 8 weeks following a 2
week run-in period. The isolated soy powder had the isoflavones
removed by repeat 95% alcohol extraction (Dishman Ltd, UK)
to give an isoflavone content of <300 parts per billion (Assayed
by FERA, Sand Hutton, UK). Casein was used as the comparator
protein (Halo Foods Ltd., Swansea, UK). All the bars used in the
study were matched for taste and macronutrient content (Halo
Foods Ltd., Swansea, UK). Randomization and labeling of the
trial supplies were done by Essential Nutrition, Brough, UK.
Study Measurements
Fasting venous blood samples were collected into serum gel,
EDTA, and fluoride oxalate Vacutainer tubes. Samples for insulin
were spun down at 3,500 g for 15min at 4◦C, within 30min
after drawing the samples, then were stored at −80◦C until
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TABLE 1 | Patient group characteristics.
SPI SP SPC SPIC P Overall
N 13 13 12 11 11 60
Gender
(male, female)
11, 2 7, 6 10, 2 10, 1 9, 2 47, 13
Age (year) 63.46 ± 6.33 66.77 ± 8.35 64.42 ± 9.53 66.91 ± 10.28 61.82 ± 7.93 64.7 ± 8.46
Diabetes control
(diet, metformin)
4, 9 4, 9 5, 7 7, 4 4, 7 24, 36
Lipid treatment (statin, no statin) 8, 5 11, 2 10,2 5, 6 9, 2 43, 17
Diabetes duration (year) 4.96 ± 4.2 3.81 ± 3.16 4.98 ± 4.30 5.14 ± 4.48 3.99 ± 3.96 4.57 ± 3.93
SPI, soy protein + isoflavones; SP, soy protein; SPC, soy protein + cocoa; SPIC, soy protein + isoflavones + cocoa; P, placebo.
analysis. Glucose, total cholesterol, triglyceride, HDL cholesterol
levels were analyzed using an enzymatic method (Synchron
LX20 analyzer, Beckman-Coulter, High Wycombe, UK).
Friedewald equation was used to determine LDL cholesterol
levels ([LDL-chol] = [Total chol]–[HDL–chol]–[TG]/2.2).
Serum insulin was measured by competitive chemiluminescent
immunoassay (DPC Immulite 2000 analyzer, Euro/DPC,
Lanberis, UK) where coefficient of variation was 8% with
an analytical sensitivity of 2 µU/ml without cross-reactivity
with proinsulin. Insulin resistance (IR) was calculated using
the Homeostasis Model Assessment (HOMA) calculation
(HOMA-IR=[insulin×glucose]/22.5) (26). The quantitative
insulin sensitivity check index (QUICKI) was calculated using
the following formula: QUICKI= 1/(log[fasting insulin µU/mL]
+ log[fasting glucose mg/dL]) (27). HbA1c was measured using
Menarini HA-8160 analysers (Menarini Diagnostics Limited).
Statistical Analysis
The sample size calculation was based on the effect of soy
phytoestrogen in post-menopausal women with diabetes (28)
and was performed using N-Query Advisor 5.0 (Statistical
Solutions, Cork, Ireland). Powered specifically for HOMA, the
minimum difference worth detecting/observed difference was
1.0, estimated within group SD was 0.9; therefore, for 80% power
and a significance level of 5%, a sample size of 10 per group
was calculated.
Results are expressed as mean ± SD where applicable. Mean
percentage changes obtained at the end of the treatment phase at
2 month were compared with the baseline results, using the one
way ANOVA with Tukey’ post-hoc testing.
Statistical analysis was performed using SPSS 22 (IBM
Corp., New York, NY) and statistical significance was defined
as (p < 0.05).
RESULTS
Baseline Characteristics
Sixty of the seventy patients who were randomized completed the
trial. Baseline patient characteristics were comparable between
the groups (Table 1).
Cardiovascular Markers, Lipids, and
Glycemic Control
The casein protein was used as a comparator and control for
the soy protein with the null hypothesis that there would be no
difference between the two proteins and that this would allow
these two groups to be combined as the placebo comparator for
the study. However, soy protein alone had a significant effect
on the percentage improvement in HbA1c (p=0.046) rejecting
the null hypothesis. Therefore, to account for the additive affect
of soy protein in the analysis, the casein arm was excluded
from the one-way ANOVA analysis and comparison of the soy
protein alone with the other soy containing arms of the study
was performed.
One-way ANOVA between the groups showed statistical
difference in percentage change in weight [F(3,56) = 3.12,
p = 0.03], percentage change in BMI [F(3,56) = 3.61, p = 0.02],
percentage change in LDL [F(3,45) = 2,94, p = 0.04] and in
percentage change in QUICKI [F(3,53) = 2.86, p< 0.05]. A Tukey
post-hoc test revealed that weight and BMI decreased significantly
in the SP group compared to the SPC group (both p = 0.05),
while LDL and QUICKI improved significantly in the SPI group
compared to the SP group (p= 0.03 and p < 0.05).
In comparison with SPI there was a significant change in the
SP group with an improvement in delta QUICKIE (SPI: −0.12
± 0.04 vs. SP: 0.03 ± 0.06, p = 0.03), delta LDL (−0.27 ± 0.41
vs. 0.22 ± 0.43, p = 0.02), percentage change in HOMA (31.02
± 54.75 vs. −14.42 ± 27.07, p = 0.02), and percentage change in
QUICKIE (−3.89± 7.07 vs. 6.11± 10.54, p= 0.01) (Table 2).
DISCUSSION
In this short term study there were significant changes in
both LDL concentration and in insulin resistance (QUICKI) in
the patient group who consumed soy protein with isoflavones,
compared to isoflavone-free soy protein. Patients who consumed
soy protein only lost weight compared to those who consumed
cocoa enriched soy protein bars.
We have previously shown that 132mg of isoflavones alone
for 3 months in a crossover study in post-menopausal women
with type 2 diabetic had no effect on glycemic control or any
cardiovascular parameter measured (16). However, when that
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same dose of isoflavone was given in combination with 30 g of soy
resulted in significant improvement in HbA1c, fasting insulin,
HOMA-IR, cholesterol, and LDL levels (28). In the present
study we found that SP without isoflavones in comparison to
casein, improved glycemic control with a change in HbA1c,
the mechanism of which remains unclear. However, in a study
comparing whey protein and soy isolate effects on an oral glucose
tolerance test, soy isolate resulted in decreased peak blood glucose
and higher insulin responses that may then reflect in improved
post-prandial glycemic control and an improved HbA1c (29).
In a randomized parallel study with obese patients with type
2 diabetes, it was shown that a soy-based diet improved weight
and glycemic control more significantly than a control diet (30).
In our short term study, weight changed minimally, though
significantly in the SP group when compared to the SPC group.
This study was of short duration to focus on glycemic
control changes and therefore not designed to look specifically
at cardiovascular risk indices. However, this study showed
improvement in LDL in the SPI group when compared to the
SP group, in accord with a meta-analysis that suggested that
the magnitude of the favorable change in serum cholesterol
and LDL levels may be affected by the baseline degree of
hypercholesterolemia (31). Whilst markers of inflammation were
not measured in this study, it has been noted that inflammatory
markers such as CRP are reduced by soy with isoflavones in type
2 diabetes, and therefore an effect on inflammation may have an
indirect and positive effect on glycemic control (32).
A recent study showed improvement in insulin resistance
measured by HOMA-IR and QUICKI, fasting glucose and
insulin, fasting triglycerides, LDL cholesterol, HDL:LDL, and
total cholesterol:HDL ratios in post-menopausal women who
consumed a food product with isoflavones and flavanols over a
1-year period, compared to placebo (33). In our shorter duration
study period, we found that any beneficial changes may be lost
by adding cocoa to the study preparations, suggesting that the
positive findings reported by others may have been abrogated by
the flavanol preparation (22).
The main limitation of the study was the relatively short
duration and the low number of patients recruited. The other
limitation is that the cocoa and soy preparations vary between the
different research studies, therefore the comparison of the results
to the literature is limited due to the difference in the quality of
the dietary products used by others.
In summary, soy protein without isoflavones had intrinsic
activity on glycemic control compared to casein with a reduction
in HbA1c. Soy alone was associated with a decrease in weight
and BMI, and soy with isoflavones improved both insulin
resistance and LDL; however, the addition of cocoa did not add
further benefits for glycemic control, insulin resistance, or the
lipid parameters.
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